Kolexia
Thomas Xavier Médecine générale
Thomas Xavier
Médecine générale
Hôpital Lyon Sud
Pierre-Bénite, France
484 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Leucémie-lymphome lymphoblastique à précurseurs B et T Maladie résiduelle Tumeurs hématologiques Chromosome Philadelphie Leucémie aiguë promyélocytaire Leucémie-lymphome lymphoblastique à précurseurs T

Collaborateurs

Voir plus
Dombret Herve
Dombret Herve
Hôpital Saint-Louis, Paris, France
Michallet Mauricette
Michallet Mauricette
Centre Léon-Bérard, Lyon, France
Raffoux Emmanuel
Raffoux Emmanuel
Hôpital Saint-Louis, Paris, France
Nicolini Franck
Nicolini Franck
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
Pharmaceutical Product Development
10 collaboration(s)
Dernière en 2020
Schlesinger Group France
5 collaboration(s)
Dernière en 2022
A+A
4 collaboration(s)
Dernière en 2023
Servier
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
Blood   07 mars 2024
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL): A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
Essai Clinique (Amgen)   01 mars 2024
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.: An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy
Essai Clinique (Novartis)   27 février 2024
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation: A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation
Essai Clinique (Forma Therapeutics, Inc.)   18 février 2024
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation: A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
Essai Clinique (Celgene)   08 février 2024
Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation.
Oncology and therapy   01 février 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Annals of hematology   26 janvier 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.
Blood advances   17 janvier 2024
Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival
65th ASH Annual Meeting Abstracts   02 novembre 2023
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
Blood advances   30 octobre 2023